Literature DB >> 28862099

Association of killer cell immunoglobulin-like receptor (KIR) genes and their HLA ligands with susceptibility to Behçet's‎ disease.

H Mohammad-Ebrahim1,2,3, E Kamali-Sarvestani1,2, M Mahmoudi3, M Beigy3,4, J Karami5, N Ahmadzadeh3, F Shahram3.   

Abstract

OBJECTIVES: Behçet's disease (BD) is a systemic inflammatory disorder with remissions and exacerbations. It is thought that defects in the natural killer (NK) cell repertoire may be involved in BD through killer cell immunoglobulin-like receptors (KIRs). This study aimed to evaluate KIR and HLA genes, their interactions in BD patients, and their associations with clinical manifestations.
METHOD: The presence or absence of KIR and HLA alleles and genotypes was analysed by polymerase chain reaction sequence-specific primer on genomic DNA of 397 BD patients and 300 healthy controls.
RESULTS: None of the KIR genes showed significant effects on BD susceptibility. HLA-C1Asn80 showed a protective effect against BD, whereas HLA-C2Lys80, HLA-B-Bw4Ile80, HLA-B5, and HLA-B51 were associated with a susceptibility risk for BD. In the combination of KIR and HLA genes, the frequencies of HLA genotypes no. 2, 3, 5, and 8, and inhibitory KIR no. 4 were significantly higher in patients than in controls. The frequencies of KIR genotype no. 3 and HLA genotypes no. 1, 4, 6, 7, and 9 were significantly lower in patients than in controls. There were many associations between KIR and HLA genes with clinical features of BD.
CONCLUSION: Differences in the frequency of HLA genes, KIR-HLA interactions, and genotypes between BD and healthy controls and their associations with clinical manifestations indicate that NK cells are involved in BD pathogenesis. The observed differences indicated an NK cell activity imbalance in BD patients, and suggest a role of the KIR-HLA repertoire in the development of BD.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28862099     DOI: 10.1080/03009742.2017.1340510

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  6 in total

1.  KIR3DL1/S1 Allotypes Contribute Differentially to the Development of Behçet Disease.

Authors:  Harry Petrushkin; Paul J Norman; Emma Lougee; Peter Parham; Graham R Wallace; Miles R Stanford; Farida Fortune
Journal:  J Immunol       Date:  2019-08-12       Impact factor: 5.422

2.  Association of Functional Polymorphisms of KIR3DL1/DS1 With Behçet's Disease.

Authors:  Ángel Castaño-Núñez; Marco-Antonio Montes-Cano; José-Raúl García-Lozano; Norberto Ortego-Centeno; Francisco-José García-Hernández; Gerard Espinosa; Genaro Graña-Gil; Juan Sánchez-Bursón; María-Rosa Juliá; Roser Solans; Ricardo Blanco; Ana-Celia Barnosi-Marín; Ricardo Gómez de la Torre; Patricia Fanlo; Mónica Rodríguez-Carballeira; Luis Rodríguez-Rodríguez; Teresa Camps; Santos Castañeda; Juan-Jose Alegre-Sancho; Javier Martín; María-Francisca González-Escribano
Journal:  Front Immunol       Date:  2019-11-29       Impact factor: 7.561

Review 3.  Natural Killer Cells in Systemic Autoinflammatory Diseases: A Focus on Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome.

Authors:  Jessica Vandenhaute; Carine H Wouters; Patrick Matthys
Journal:  Front Immunol       Date:  2020-01-15       Impact factor: 7.561

Review 4.  Natural Killer Cells: Potential Biomarkers and Therapeutic Target in Autoimmune Diseases?

Authors:  Elena Gianchecchi; Domenico V Delfino; Alessandra Fierabracci
Journal:  Front Immunol       Date:  2021-02-19       Impact factor: 7.561

5.  Hypoferritinemia and iron deficiency in youth with pediatric acute-onset neuropsychiatric syndrome.

Authors:  Avis Chan; Hannah Karpel; Ellen Spartz; Theresa Willett; Bahare Farhadian; Michael Jeng; Margo Thienemann; Jennifer Frankovich
Journal:  Pediatr Res       Date:  2020-08-03       Impact factor: 3.756

6.  Analysis of Killer Cell Immunoglobulin-Like Receptor Genes and Their HLA Ligands in Inflammatory Bowel Diseases.

Authors:  Fereshteh Beigmohammadi; Mahdi Mahmoudi; Jafar Karami; Nooshin Ahmadzadeh; Nasser Ebrahimi-Daryani; Nima Rezaei
Journal:  J Immunol Res       Date:  2020-09-19       Impact factor: 4.818

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.